TickerFacts.

Acumen Pharmaceuticals, Inc. (ABOS): Cash & Equivalents

Annual figures by period end, from SEC filings.

$53.99M
As of 2025-12-31
$59.44M
As of 2026-06-30
-25.4%
3-year compound annual growth
+4.3%
5-year compound annual growth
$130.10M2020-12-31: $43.78M2021-12-31: $122.16M2022-12-31: $130.10M2023-12-31: $66.89M2024-12-31: $35.63M2025-12-31: $53.99M$53.99M
2020-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$53.99M+51.5%2026-03-26, Balance as of period end
2024-12-31$35.63M-46.7%2026-03-26, Balance as of period end
2023-12-31$66.89M-48.6%2025-03-27, Balance as of period end
2022-12-31$130.10M+6.5%2024-03-26, Balance as of period end
2021-12-31$122.16M+179.1%2022-03-28, Balance as of period end
2020-12-31$43.78Mn/a2022-03-28, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31$53.99M+51.5%
Kalaris Therapeutics, Inc. (KLRS)2025-12-31$98.05Mn/m
Candel Therapeutics, Inc. (CADL)2025-12-31$119.73M+16.6%
Humacyte, Inc. (HUMA)2025-12-31$50.50M+12.4%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$17.97Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31$26.70M-33.6%
Zura Bio Ltd (ZURA)2025-12-31$109.41M-38.0%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$40.79M-10.9%
Palisade Bio, Inc. (PALI)2025-12-31$133.38Mn/m

Compare ABOS, KLRS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗